GR1803 for Multiple Myeloma with Soft Tissue Spread
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called GR1803 for people with multiple myeloma that has spread to soft tissue areas outside the bone. The goal is to see if it can help shrink these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have multiple myeloma that has spread to areas outside the bone marrow, called extramedullary plasmacytoma.
- You are able to care for yourself and are up and about (ECOG score 0 to 2).
- You have not been treated with a therapy that targets the BCMA protein before.
- Your multiple myeloma does not involve the brain or spinal cord, and you do not have other rare plasma cell disorders like plasma cell leukemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
Hear when a new Multiple Myleoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.